chrisvoncsefalvay/vaers-outcomes huggingface dataset:
COVID-19 TEST POSITIVE; This spontaneous report received from a patient (health care professional) via other manufacturer (Pfizer ) concerned a 23 year old female.  The patient's height, and weight were not reported. Patient was other healthcare professional. The patient was not pregnant at the time of vaccination. The patient received covid-19 vaccine ad26.cov2.s (dose number in series 1) (suspension for injection, route of admin, batch number and expiry were not reported) dose was not reported, 1 total administered on 12-APR-2021 for prophylactic vaccination. Age at time of vaccination 22 years old. The batch number was not reported and has been requested. Concomitant medications included Plaqnil (hydroxychloroquine phosphate) for drug use for unknown indication. It was unknown whether patient had any adverse events following vaccination with first dose of covid-19 vaccine ad26. cov2.s (dose number in series 1). The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient additionally received non-company suspect vaccine Pfizer Biontech Covid-19 vaccine (tozinameran) (dose number in series 2) form of administration, route of administration, batch number and expiry were not reported), dose was not reported, start therapy date was not reported, administered on 29-OCT-2021 for prophylactic vaccination. Age at time of vaccination 22 years old. It was unknown whether patient had any adverse events following vaccination with second dose of covid-19 vaccine ad26. cov2.s (dose number in series 2). The patient additionally received non-company suspect vaccine Pfizer Biontech Covid-19 vaccine (tozinameran) (dose number in series 3) form of administration, route of administration, batch number and expiry were not reported, dose was not reported, start therapy date was not reported, administered on 30-APR-2022 for prophylactic vaccination. Age at time of vaccination 23 years old. On 07-JUN-2022, the patient tested positive for covid-19 infection and started treatment with Paxlovid (dose number in series 3). The patient was prescribed with non-company drug Paxlovid (form of admin, route of admin, batch number and expiry were not reported) dose was not reported, administered first dose on 07-JUN-2022 and last dose on 11-JUN-2022 for covid-19 treatment. On 11-JUN-2022, patient tested negative with covid-19 test (dose number in series 3). From 12-JUN-2022 to 21-JUN-2022, the patient tested negative everyday (dose number in series 3). On 22-JUN-2022, the patient tested positive for 22-JUN-2022 (dose number in series 3). The action taken with tozinameran and tozinameran was not applicable. The patient had not recovered from covid-19 test positive. This report was non-serious.
11:30 pt had DTP & HIB in lt arm as well as MMR in rt arm;pt immed exp hives like rash & some redness & swelling lt arm;(this was #1 DTAP & #1 HIB) pt had HDTP in past;send to MD;
Patient received JJ and requested to get moderna as supplemental. Provider okayed this and the staff member gave patient the supplemental full dose. Per the guidelines patients that received their first dose and are supplemental patients should get the same vaccines as boosters and supplemental. Patient should have received JJ or if they had received booster they should have gotten half dose. Patient was made aware by provider.
I woke up the next day feeling slight nausea, slight pain in my right arm and fatigue, I slept most of the day.  By 4:30 PM I felt much better and all my symptoms disappeared.  No body aches.
2nd parent missed 2nd dose, past 36 days.; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (2nd parent missed 2nd dose, past 36 days.) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 25-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (2nd parent missed 2nd dose, past 36 days.). At the time of the report, PRODUCT DOSE OMISSION ISSUE (2nd parent missed 2nd dose, past 36 days.) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medication was provided. No treatment medications were not provided.   This case was linked to US-irms-MOD21-269732 (E2B Linked Report).; Sender's Comments:  US-irms-MOD21-269732:
mom notified nurse during waiting period of possible rash developing on patient's face.  Patient had been crying hard during vaccination,  blotching around eyes and cheeks visible, no hives.  injection site clear, no visible rash or hives on abdomen or back, airway is unobstructed.  Mom requested Benedryl to be given. Benedryl 12.5 mg given po at 1340.  1350 Patients blotches improved 1400 patient's face clear
On 10/20/2022, Kinrix administered to patient as 3rd dose of Dtap and 3rd dose of Polio to a three-year-old child who is on a catch-up schedule for his vaccinations. Error discovered by Billing/Coding Department on 10/24/2022. Nurse notified on 10/25/2022. System indicates doses as valid. Nurse who administered the dose, spoke with Kinrix manufacturer (GSK) regarding the situation. Employee provided Nurse with references that validate Kinrix as 3rd dose of Dtap and Polio vaccines.
This spontaneous report as received from a consumer's mother refers to a patient of unknown age. The reporter's daughter experienced seizure-like reaction, the patient convulsed for "2-3 seconds" and then "passed out" for a "few seconds" after receiving first dose of GARDASIL. (Captured in case 1308USA009926). The patient's mother called the office after her child's reaction and stated that she has done some research (source unknown) and found out that seizure-like reaction was common after GARDASIL administration and she also found from her research that someone has died from GARDASIL reaction and was concerned. In this unconfirmed AE report was reported on an unknown date this patient was vaccinated with GARDASIL (dosing information and route are unknown). On an unknown date this patient experienced GARDASIL reaction. The outcome of GARDASIL reaction was reported as fatal. No reporter causality provided. No consent to contact physician. Additional information is not expected.
TOOK TWO DOSES IN A ROW; This spontaneous case (PVX2019-1265) was received from a pharmacist on 20-May-2019. It describes a female consumer who "took two doses in a row". The consumer was receiving Vivotif for an unknown indication.  Case report: The consumer took the first and the second dose of Vivotif on consecutive days.  Action taken with Vivotif was not applicable.  The clinical outcome of the event was unknown.  Company's Comment: The causality of the event "took two doses in a row" was considered as not applicable.; Sender's Comments: Company's Comment: The causality of the event "took two doses in a row" was considered as not applicable.
after receiving the pfizer covid vaccine on Friday 10-19-2021 I had several reactions. The normal ever and aches. As of Monday I have had strange nerve pain in arms and legs. Now I have sever pain in my right ankle and restricted movement. It is very painful to even walk. It has got worse by the day.
This spontaneous report was received from a pharmacist, concerning a 60 year-old female patient. There were no concurrent conditions, medical history or concomitant medications reported. The patient presented a codeine drug reaction/allergy. On 21-APR-2017, the patient was subcutaneously vaccinated with a dose of ZOSTAVAX (dose, frequency, lot # and expiration date were not reported) for prophylaxis (reported as "vaccination"). On 22-APR-2017, a rash appeared on the patient's injection site; this rash was described as warm, red and slightly raised. The pharmacist was unaware of any treatment patient received before returning to pharmacy on 24-APR-2017. It was reported that packet was offered and the health care professional (HCP) was adamant about not receiving, so packet was not faxed. At the time of the report, she had not recovered from the adverse event. The causality between the adverse event and ZOSTAVAX was unknown.  Additional information has been requested.
Patient reported did not feel the vaccine given at time of administration and had normal muscle soreness later in the evening. The next day pain radiated toward front of shoulder, then later to the back of shoulder. Pain has progressively gotten worse each morning affecting mobility/range of motion. Pain is reported as nerve pain in left arm in the back upper area.
PT RECIEVED HIS 5TH ANTHRAX VACCINE ON 9 JAN 03. PT DEVELOPED A FEVER WITH A TEMP OF APPROX 102, BY SUBJECTIVE FOR A COUPLE OF DAYS. fEVERS DISAPPEARED. PT BEGAN TO HAVE SLOUGHING OF EPIDERMIS ON BOTTOM OF RIGHT AND HAND, NO OTHER AREAS WERE AFFECTED. PT WAS TX'D ON 27 JAN 03 WHEN HE REPORTED TO THE BMC FOR EXAMINATION. TX'D WITH EUCERIN CREAM TID TO AFFECTED AREA WITH GOOD RESULTS. NO SPECIFIC CAUSE FOR CONDITION IS NOTED, QUESTIONABLE REACTION TO VACCINE.
sore arm/Soreness in my arm; tiredness/May be little bit tired; She feels like she hasn't had anything; This is a spontaneous report from a contactable consumer.    A 66-years-old female patient received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, Lot Number: EN6203; Expiration Date: Unknown) via an unspecified route of administration on 24Feb2021 (age at vaccination 66 years old) as dose 2, single for COVID-19 immunization. The patient medical history was not reported. There were no concomitant medications. The patient previously received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, Lot Number: EN9581; Expiration Date: Unknown) via an unspecified route of administration on 03Feb2021 as dose 1, single for covid-19 immunization. Patient stated that she had the vaccine, the second dose of the Pfizer vaccine on Wednesday afternoon and she really have not had any reactions. know just have soreness in her arm and may be little bit tired on 24Feb2021, she was yesterday that would have been the first day after but that's all.  Also added that (25Feb2021)   Right, today she was not tired but she was little bit yesterday, just a little bit not bad and she have a walk 3 and half so it would might be that. On an unknown date in Feb2021, she felt like she hasn't had anything. The outcome event feeling abnormal was unknown and patient recovered from other events in Feb2021.  No follow-up attempts are possible. No further information is expected.
Punctured Janssen COVID 19 vaccine vial was left at room temperature for 2 hours longer the manufacture recommended time. First punctured was at 11:45a, and vaccine was given at 3:42pm. Patient has headache and sore arm the next day but no other symptoms.
Pt presented w/ slurred speech, ataxia, dizziness, hand numbness, ophthalmoplegia. Found to have Miller Fisher variant of Guillain Barre Syndrome. Required admission to Neuro ICU and plasmapheresis therapy. Currently hospitalized.
Within 5 minutes of getting vaccine patient started feeling dizzy, had a headache and had an itchy throat. Offered Benadryl but patient was allergic. Offered Epi-pen but patient refused 3 times. Gave her water for her itchy throat. She stated she will be fine and wanted to leave. She had no trouble breathing  but kept clearing throat. Called patient an hour later to check up on her and did not answer, so I left a voicemail. Called her back an hour after the first call and husband answered. Stated he took her to the emergency room where they gave her Prednisone.
**No adverse reactions noted** Patient received Moderna 2nd vaccination 2 days early, patients return appointment was scheduled in error after 1st vaccination, I realized the error when charting vaccination.
This spontaneous report as received from a registered nurse refers to approximately 17 year old patient of unknown gender. No information provided regarding medical history and concurrent conditions. On 10-JUN-2014 the 17 year old patient was inadvertently vaccinated with PROQUAD, subcutaneous (dose number, lot#, anatomical location not reported). No concomitant medications reported. No adverse effects reported. Additional information has been requested.
Patient called clinic earlier today and reported she noted redness and pain at the injection site starting on 08/12/2017. She reported low grade fever of 100.1 oral, shortness of breath, body aches,  and neck stiffness starting today 08/14/2017. She was asked to report to the ER for STAT evaluation. She opted to see her PCP today and reported she has shortness of breath almost daily due to her sarcoidosis. She was seen by her PCP today. She came to Rediclinic after her PCP visit  and she was in No acute distress. Immunization site: redness/erythematous circular patch at the injection site 7.5 cm X 6 cm with mild overlying warmth, tender to touch. Patient was treated for her chest congestion and vaccine site reaction -suspected infection by her PCP with azithromycin (ZPACK) and prednisone 10 mg one PO QD X 10 days.
RECOMBN AX Hb that was improperly stored; This spontaneous report was received from a registered nurse and refers to a patient of unknown age and gender. There was no information about patient's concomitant medications, concurrent conditions or pertinent medical history.  On 27-JUL-2020, the patient was vaccinated with an onetime dose of hepatitis b vaccine (recombinant)(RECOMBIVAX HB), thimerosal free, lot number R034547 with expiration date 06-JUN-2021 (dose, route and anatomical location were not reported) which was improperly stored, for prophylaxis. The vaccine was exposed to 11.8 Celsius degrees (C) for 48 minutes. There was no previous temperature excursion, digital data logger was filled.
Ten minutes after shot suddenly patient felt like he was going to pass out (Tunnel vision and dizzy). Walked around for awhile. Wrists hurt with sweaty palms. Sides of head hurt. Cold tingle around spine (lower to middle back). Trouble breathing for a little bit. 1000 mg EPI given IM, 50mg Benadryl given IM.
allergic reaction after the second dose within 5-10 minutes; warm sensation in his ears; hives; This is a spontaneous report from a contactable consumer (patient). A 53-year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Batch/Lot Number: EW0151), intramuscular, administered in Deltoid Left on 09Apr2021 (at the age of 53years) as dose 2, single for Covid-19 immunization. Historical vaccine included BNT162B2 (lot number: EL9266) on 13Mar2021 for Covid-19 immunization; he did not have any issues after the first dose. Medical history included allergy to shellfish, asthma/asthmatic (since birth), immunocompromised, and Behcet's disease (years ago, never treated for it continuously); Hodgkins Cancer (father), non-small cell (as reported) (brother), and breast cancer (mother). The patient's concomitant medications were not reported. It was reported that the patient had an allergic reaction after the second dose within 5-10 minutes with a warm sensation in his ears and hives. Hives that started in neck and forehead then went to throat and chest; the patient also had warm sensation in ears. He clarified that he started having a warm sensation in his ears. He then got hives which started in neck and had a little on forehead but closer to throat and chest. It was very mild. The patient was sent to the Emergency Room and received two doses of Benadryl. When he took 1st dose of Benadryl, it helped a little bit and he was still itching, but it was not intensive. Then the doctors came in and gave another dose of Benadryl. He added the event was caught in time and he was given 2 doses of Benadryl in Emergency room. He stayed for 3 hours and everything was fine after that. The patient asked if it is safe to receive the booster dose. He stated that one of his doctor's said not to get it, 1 doctor said to get it and then the other doctor said to get it and be monitored slowly.  He wanted to get his own research from Pfizer. The outcome of events was unknown. The reporter seriousness for Hives that started in neck and forehead then went to throat and chest was unspecified.  Follow-up attempts are completed. No further information is expected.
This case was considered medically important for the event of autism. Information regarding Prevnar (pneumococcal 7 valent conjugate vaccine (diphtheria crm197 protein) injection) was received from a consumer via a regulatory authority regarding a 21 month old female autistic pt who accidentally received a 5th dose of Prevnar which reportedly made the child's autism worse. The pt received the fifth dose on an unspecified date. The pt's concurrent illness includes autism (age of onset 1). Indication for Prevnar was immunization. Product was administered on an unspecified date. Dose regimen was 1 dose 1 time per day. Additional suspect medication included Daptacel (diphtheria and tetanus toxoids/acellular pertussis vaccine adsorbed). Concomitant medications were not reported. A nurse reported that she received a call from the mother of an autistic child who accidentally was given a 5th dose of Prevnar (accidental overdose) (incorrect dose administered) on an unspecified date. The mother stated that 2-3 days after vaccination, the child's autism got worse (autism) (condition aggravated). The child is now about 3 yrs of age. The mother declined further information.
Lower lip left side (vaccine in left shoulder) became tingling, numb, pins and needles feeling 45 mins to 1 hour after shot, and eyelids were puffy and slightly sagging. Lip felt that way for 3-4 days.
Tongue swelling, facial swelling, .  Varies in severity but is constant.  When swelling is severe experiences shortness of breath, difficulty swallowing, difficulty speaking, difficulty swallowing ,facial swelling from beneath eyes to chin . notes no aggravating factors.  Does have a red rash On arms and back.
2021-00015215 The patient felt dizzy after her first injection, and also today after her second dose of Pfizer. She refused medical treatment and we kept her in rcovery for 45 minutes. All vitals monitored were within normal limits. She signed and against medical advice form and her husband drove her home.
This case was reported by a consumer via call center representative and described the occurrence of pain in a 91-year-old female patient who received SHINGRIX for prophylaxis. On 28th June 2018, the patient received the 1st dose of SHINGRIX. On an unknown date, less than a year after receiving SHINGRIX, the patient experienced pain. On an unknown date, the outcome of the pain was recovered/resolved. It was unknown if the reporter considered the pain to be related to SHINGRIX. Additional details were received as follows: The age at vaccination was not reported. The patient experienced mild soreness after vaccination with SHINGRIX.
This spontaneous report as received from a nurse refers to a 16 year old female patient. On 22-JUL-2014 the patient was supposed to vaccinate with the second dose of M-M-R II (lot #, expiration date, route, frequency and dose were unknown) and (Oka/Merck) VARIVAX (lot #, expiration date, route, frequency and dose were unknown). But the patient was vaccinated with a dose of (Oka/Merck) PROQUAD (lot #, expiration date, route, frequency and dose were unknown) in error. No adverse effect was reported. The (Oka/Merck) PROQUAD was not administered to the patient as a result of medication confusion.  Additional information has been requested.
Day 1: Received MENACTRA and Tdap. Day 2: Received IPV and PNEUMOVAX developed chills 2-2.5 hrs later; Returned to clinic. BP 128/89, T 98.1F oral. HR 89 RR 16, O2 sat 100>. Pt had gatorade. Warm tea, rest and monitoring, felt much better in a late day 3: Developed 2 areas soreness and erythema below vaccine sites. Day 4-5: developed subjective feeling of fever, but did not take temp, and sweating. Day 9: +/check at clinic-doing well.
Received Td 6/29/04 next day in AM started with pain and reddened around injection site today 7/1/04 started itching. Feels warm to touch and reddened like hives.
Lightheaded/Dizzy; metallic taste in mouth; Rapid heart rate; tingly sensation in mouth; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 51 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), intramuscular, administered in arm left, administration date 21Apr2021 10:55 (Lot number: EW0164) at the age of 51 years as dose 1, single for covid-19 immunisation. Relevant medical history included: "Mild Asthma", start date: 1996 (ongoing), notes: Onset date: 1996; "heart murmur" (unspecified if ongoing); "Heart attack", start date: 1997 (ongoing); "known allergies: Yes" (unspecified if ongoing). Concomitant medication(s) included: ASPIRIN [ACETYLSALICYLIC ACID] taken for myocardial infarction, start date: 1997 (ongoing). The following information was reported: DIZZINESS (non-serious) with onset 21Apr2021 10:59, outcome "recovered" (2021), described as "Lightheaded/Dizzy"; DYSGEUSIA (non-serious) with onset 21Apr2021 10:59, outcome "recovered" (2021), described as "metallic taste in mouth"; HEART RATE ABNORMAL (non-serious) with onset 21Apr2021 10:59, outcome "recovered" (2021), described as "Rapid heart rate"; PARAESTHESIA ORAL (non-serious) with onset 21Apr2021 10:59, outcome "recovered" (2021), described as "tingly sensation in mouth". Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were not taken as a result of dizziness, dysgeusia, heart rate abnormal, paraesthesia oral. Additional information: Patient did not receive any other vaccine in four weeks. Patient did not had covid prior vaccination and was not covid tested post vaccination. Approximately 3 minutes after my shot, I got a strong metallic taste in my mouth, I felt as through I might faint (which I have never done in my life), my heart started racing, I was dizzy/"Woozy". The metallic taste + wooziness passed within 15 minutes. My heart was racing/pounding for approximately an hour, as I was driving home (after the 15 minute mark), I got a weird tingly feeling in my mouth. This resolved within an hour. I did not experience any swelling and trouble breathing, which is why I did not seek medical treatment. All symptoms disappeared within a couple hours. Patient did not seek treatment afterward. patient did not require medical treatment at the site. patient just sat on patient car until patient felt it was safe to drove. Seriousness Criteria was Not serious  Follow-up attempts are completed. No further information is expected.